New York, April 14, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Non-alcoholic Steatohepatitis (NASH) Industry" - https://www.reportlinker.com/p06044755/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Non-alcoholic Steatohepatitis (NASH) Market to Reach $160.7 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Non-alcoholic Steatohepatitis (NASH) estimated at US$4.8 Billion in the year 2022, is projected to reach a revised size of US$160.7 Billion by 2030, growing at aCAGR of 55% over the period 2022-2030. Vitamin E & Pioglitazone, one of the segments analyzed in the report, is projected to record 45.7% CAGR and reach US$53.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Obeticholic Acid (OCA) segment is readjusted to a revised 43.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 51.9% CAGR
The Non-alcoholic Steatohepatitis (NASH) market in the U.S. is estimated at US$1.6 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$24 Billion by the year 2030 trailing a CAGR of 51.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 46.6% and 45.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 35.4% CAGR.
Select Competitors (Total 12 Featured)
- AstraZeneca PLC
- Conatus Pharmaceuticals Inc.
- Galmed Pharmaceuticals Ltd.
- Genfit SA
- Gilead Sciences, Inc.
- Immuron Ltd.
- Intercept Pharmaceuticals, Inc.
- Zydus Cadila
Read the full report: https://www.reportlinker.com/p06044755/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Non-alcoholic Steatohepatitis (NASH) - Global Key Competitors
Percentage Market Share in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR
Table 2: World Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 3: World 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2014, 2023 &
2030
Table 4: World Recent Past, Current & Future Analysis for
Vitamin E & Pioglitazone by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 5: World Historic Review for Vitamin E & Pioglitazone by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 6: World 16-Year Perspective for Vitamin E & Pioglitazone
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for
Obeticholic Acid (OCA) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 8: World Historic Review for Obeticholic Acid (OCA) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 9: World 16-Year Perspective for Obeticholic Acid (OCA)
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Elafibranor by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR
Table 11: World Historic Review for Elafibranor by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 12: World 16-Year Perspective for Elafibranor by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis for
Selonsertib & Cenicriviroc by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 14: World Historic Review for Selonsertib & Cenicriviroc
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 15: World 16-Year Perspective for Selonsertib &
Cenicriviroc by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2014, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis for
Hospital Pharmacy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 17: World Historic Review for Hospital Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 18: World 16-Year Perspective for Hospital Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis for
Online Provider by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 20: World Historic Review for Online Provider by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 21: World 16-Year Perspective for Online Provider by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis for
Retail Pharmacy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 23: World Historic Review for Retail Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 24: World 16-Year Perspective for Retail Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2014, 2023 & 2030
Table 25: World Non-alcoholic Steatohepatitis (NASH) Market
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2030
III. MARKET ANALYSIS
UNITED STATES
Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United States
for 2023 (E)
Table 26: USA Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 27: USA Historic Review for Non-alcoholic Steatohepatitis
(NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic
Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2014 through 2021 and % CAGR
Table 28: USA 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 29: USA Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 30: USA Historic Review for Non-alcoholic Steatohepatitis
(NASH) by Sales Channel - Hospital Pharmacy, Online Provider
and Retail Pharmacy Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Table 31: USA 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
CANADA
Table 32: Canada Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 33: Canada Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 34: Canada 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 35: Canada Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 36: Canada Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 37: Canada 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
JAPAN
Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 38: Japan Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 39: Japan Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 40: Japan 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 41: Japan Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 42: Japan Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 43: Japan 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
CHINA
Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 44: China Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 45: China Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 46: China 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 47: China Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 48: China Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 49: China 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
EUROPE
Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 50: Europe Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 51: Europe Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2014 through 2021 and %
CAGR
Table 52: Europe 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK and
Rest of Europe Markets for Years 2014, 2023 & 2030
Table 53: Europe Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 54: Europe Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 55: Europe 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 56: Europe Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 57: Europe Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 58: Europe 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
FRANCE
Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 59: France Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 60: France Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 61: France 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 62: France Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 63: France Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 64: France 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
GERMANY
Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 65: Germany Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 66: Germany Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 67: Germany 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 68: Germany Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 69: Germany Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 70: Germany 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
ITALY
Table 71: Italy Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 72: Italy Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 73: Italy 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 74: Italy Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 75: Italy Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 76: Italy 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
UNITED KINGDOM
Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United Kingdom
for 2023 (E)
Table 77: UK Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 78: UK Historic Review for Non-alcoholic Steatohepatitis
(NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic
Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2014 through 2021 and % CAGR
Table 79: UK 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 80: UK Recent Past, Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 81: UK Historic Review for Non-alcoholic Steatohepatitis
(NASH) by Sales Channel - Hospital Pharmacy, Online Provider
and Retail Pharmacy Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
Table 82: UK 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
REST OF EUROPE
Table 83: Rest of Europe Recent Past, Current & Future Analysis
for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin
E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 84: Rest of Europe Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 85: Rest of Europe 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 86: Rest of Europe Recent Past, Current & Future Analysis
for Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 87: Rest of Europe Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 88: Rest of Europe 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
ASIA-PACIFIC
Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Asia-Pacific for
2023 (E)
Table 89: Asia-Pacific Recent Past, Current & Future Analysis
for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin
E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 90: Asia-Pacific Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 91: Asia-Pacific 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 92: Asia-Pacific Recent Past, Current & Future Analysis
for Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 93: Asia-Pacific Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 94: Asia-Pacific 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
REST OF WORLD
Table 95: Rest of World Recent Past, Current & Future Analysis
for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin
E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2022 through 2030 and %
CAGR
Table 96: Rest of World Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 97: Rest of World 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2014, 2023 & 2030
Table 98: Rest of World Recent Past, Current & Future Analysis
for Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 99: Rest of World Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR
Table 100: Rest of World 16-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2014, 2023 & 2030
IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06044755/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
![](https://ml.globenewswire.com/media/MWNhOTUwNTYtN2EyMC00YjkxLThiODUtOTczNGNmZjU3MGVlLTExOTk4MTE=/tiny/ReportLinker.png)